Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 1972-1974, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duffy, M. J.
Right arrow Articles by Smith, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duffy, M. J.
Right arrow Articles by Smith, C.

Clinical Chemistry, Vol 32, 1972-1974, Copyright © 1986 by American Association for Clinical Chemistry

Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies

MJ Duffy, L O'Siorain, B Waldron and C Smith

Our aim here was to compare a new enzyme immunoassay for estradiol receptors (ER) in breast cancer with a standard assay involving radiolabeled estradiol. A significant correlation was obtained between the standard binding assay and immunoassay (rs = 0.945, p less than 0.001, n = 100). Immunoreactive ER were also found in endometrial carcinomas but not in lung carcinomas, malignant melanomas, or basal cell carcinomas. Patients with breast cancers containing immunoreactive ER survived significantly longer after operation than patients whose tumor lacked immunoreactive ER. This immunoassay for ER is simpler than the binding assay and requires less time and tissue.


The following articles in journals at HighWire Press have cited this article:


Home page
 Ann OncolHome page
B. M. Ryan, G. E. Konecny, S. Kahlert, H.-J. Wang, M. Untch, G. Meng, M. D. Pegram, K. C. Podratz, J. Crown, D. J. Slamon, et al.
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ann. Onc., April 1, 2006; 17(4): 597 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Konecny, M. Untch, J. Arboleda, C. Wilson, S. Kahlert, B. Boettcher, M. Felber, M. Beryt, S. Lude, H. Hepp, et al.
HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer
Clin. Cancer Res., August 1, 2001; 7(8): 2448 - 2457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Konecny, M. Untch, A. Pihan, R. Kimmig, M. Gropp, P. Stieber, H. Hepp, D. Slamon, and M. Pegram
Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer
Clin. Cancer Res., June 1, 2001; 7(6): 1743 - 1749.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.